Report
Franc Gregori ...
  • Lala Gregorek
  • Philippa Gardner

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: The China sales decline, plus lowering of revenue guidance are undoubtedly disappointing. However, China growth is already improving and management is confident this will continue during H225, driven by new indications. In particular, the recent Orpathys/Tagrisso approval based on SACHI data represent a much larger indication; importantly, data from the global SAFFRON trial are expected H126. Furthermore, as the sizeable ATTC opportunities become clearer, these could offer significant upside potential; additional information is expected at the EORTC conference in October and clinical trials for the first ATTC candidate should start by end-2025. Data from surufatinib in pancreatic cancer, expected late-2025, remain a wild-card to which we assign limited value. Our most recent HUTCHMED valuation is $5.86bn/ £4.69bn/HK$45.74bn, or $33.64/ADS and 538p/HK$52.48 per share.
Underlying
Hutchison China Meditech Ltd Sponsored ADR

Provider
Trinity Delta
Trinity Delta

We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.

The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.

We also firmly believe that by putting our clients first, we create long term value for all stakeholders.

Analysts
Franc Gregori

Lala Gregorek

Philippa Gardner

Other Reports on these Companies
Other Reports from Trinity Delta

ResearchPool Subscriptions

Get the most out of your insights

Get in touch